# US 6,730,670 B2 · 7-phenyl-benzo[b]thiophen amide derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,730,670 B2
- Document ID: US6730670B2
- Status: Granted
- Kind: B2
- Application number: 10/315,821
- Filed: 2002-12-10
- Published: 2003-08-07
- Granted: 2004-05-04
- Earliest claimed: 2001-12-12
- Assignees: Hoffmann-La Roche Inc.
- Inventors: Alexander Alanine; Alexander Flohr
- Web page: https://patentgrep.com/patent/US6730670B2

## CPC

- C07D 409/12: linked by a chain containing hetero atoms as chain links
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/06: Antiasthmatics
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/04: Centrally acting analgesics, e.g. opioids
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 25/30: for treating abuse or dependence
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 333/66: Nitrogen atoms not forming part of a nitro radical
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A compound of the formula Compounds of formula I have a good affinity to the A2A receptor and are useful for the treatment of diseases mediated by this receptor.

## Claims

### Claim 1

A compound of the formula
wherein
R is selected from the group phenyl, phenyl substituted by halogen, pyridin 3-or 4-yl, pyridin 3- or 4-yl substituted by lower alkyl and —NR1R2, wherein R1 and R2, together with the N atom to which they are attached, form heterocyclic rings, selected from the group consisting of
morpholinyl, thiomorpholinyl, piperidinyl and piperazinyl, said heterocyclic rings being unsubstituted or substituted by —(CH2)n-hydroxy, lower alkyl or lower alkoxy; and
n is 0, 1 or 2;
or a pharmaceutically acceptable acid addition salt thereof.

### Claim 2 (depends on 1)

(Original) The compound of formula I in accordance with claim 1, wherein R is thiomorpholinyl.

### Claim 3 (depends on 2)

The compound of formula I in accordance with claim 2, wherein the compound is thiomorpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-amide.

### Claim 4 (depends on 1)

The compound of formula I in accordance with claim 1, wherein R is morpholinyl.

### Claim 5 (depends on 4)

The compound of formula I in accordance with claim 4, wherein the compound is morpholine-4-carboxylic acid (4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-amide.

### Claim 6 (depends on 1)

The compound of formula I in accordance with claim 1, wherein R is piperidinyl or piperidinyl substituted by hydroxy, methoxy or —CH2OH.

### Claim 7 (depends on 6)

The compound of formula I in accordance with claim 6, wherein the compound is selected from the group consisting of piperidine-1-carboxylic acid (4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-amide, 4-hydroxy-piperidine-1-carboxylic acid (4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-amide, 4-methoxy-piperidine-1-carboxylic acid (4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-amide and 4-hydroxymethyl-piperidine-1-carboxylic acid (4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-amide.

### Claim 8 (depends on 1)

The compound of formula I in accordance with claim 1, wherein R is piperazinyl, substituted by methyl.

### Claim 9 (depends on 8)

The compound of formula I in accordance with claim 8, wherein the compound is 4-methyl-piperazine-1-carboxylic acid (4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-amide.

### Claim 10 (depends on 1)

The compound of formula I in accordance with claim 1, wherein R is selected from the group phenyl, phenyl substituted by halogen, pyridin 3- or 4-yl and pyridin 3- or 4-yl substituted by lower alkyl.

### Claim 11 (depends on 10)

The compound of formula I in accordance with claim 10, wherein the compound is selected from the group consisting of N-(4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-6-methyl-nicotinamide, N-(4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-2-methyl-isonicotinamide and 4-fluoro-N-(4-methoxy-7-phenyl-benzo[b]thiophen-2-yl)-benzamide.

### Claim 12

A process for preparing a compound of formula IA comprising
a) reacting a compound of formula
with a compound of formula
RC(O)Cl (3)
forming a compound of formula
wherein R is phenyl, phenyl substituted by halogen, pyridin 3-or 4-yl, or pyridin 3-or 4-yl substituted by lower alkyl.

### Claim 13

A process for preparing a compound of formula IB comprising
a) reacting a compound of formula
with a compound of formula HNR1R2
forming a compound of formula
wherein R1 and R2, together with the N atom to which they are attached, form heterocyclic rings, selected from the group consisting of morpholinyl, thiomorpholinyl, piperidinyl and piperazinyl, said heterocylic rings being unsubstituted or substituted by —(CH2)n-hydroxy, lower alkyl or lower alkoxy.

### Claim 14 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula I according to claim 1, or a pharmaceutically acceptable salt thereof and a pharmaceutically inert carrier.

### Claim 15

A method for the treatment of Parkinson's disease comprising administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof to a person in need of such treatment.

### Claim 16

A method for the treatment of ischemia comprising administering a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof to a person in peed of such treatment.
